Use of biomarkers to determine whether a subject has suffered, may have suffered, or is suspected to have suffered subacute acquired brain injury (ABI).

The detection of GFAP and UCH-L1 biomarkers in TBI patients post-injury aids in objective assessment and monitoring, addressing the lack of accurate TBI diagnosis and management by providing sensitive and reliable recovery insights.

JP2026517628APending Publication Date: 2026-06-02ABBOTT LAB INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
ABBOTT LAB INC
Filing Date
2024-04-04
Publication Date
2026-06-02

Smart Images

  • Figure 2026517628000001
    Figure 2026517628000001
  • Figure 2026517628000002
    Figure 2026517628000002
  • Figure 2026517628000003
    Figure 2026517628000003
Patent Text Reader

Abstract

This specification discloses a method for detecting the level of at least one biomarker, glial fibrillary acidic protein (GFAP), in one or more samples taken from subjects such as human subjects, which can help determine whether a subject has suffered or may have suffered acquired brain injury, such as traumatic brain injury (TBI).
Need to check novelty before this filing date? Find Prior Art